Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79640.510.0434%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Dermata Therapeutics Inc

DRMANASDAQ
Trade with Public
Trade with Public
$1.21
-0.02-1.63%
At close: Sep 4, 5:00 PM EST
$1.29
0.0786.45%
After Hours: 6:38 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Dermata Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dermata Therapeutics (DRMA).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$10Upside to Avg. PT+676.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2025Maxim GroupAnthony VendettiPT CutBuy$30→$10
May 21, 2025Maxim GroupAnthony VendettiPT CutBuy$6→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $30 to $10.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $6 to $3.
Benzinga Newsdesk

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.
Rishabh Mishra

Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $10 to $6.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $16 to $4.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved